[{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Isofol Medical \/ Solasia","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Solasia"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"PALADIN LABS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Isofol Medical \/ Paladin Labs","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Paladin Labs"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Isofol Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : In AGENT study, patients with non-resectable mCRC treated with arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab did not achieve a statistically significant overall response rate of ≥ 10% as compared to patients treated with the stand...

                          Brand Name : Modufolin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 25, 2022

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Progression-free survival (PFS) was approximately 12.8 months for the arfolitixorin arm and 11.6 months for the control arm, with a P-value of 0.76. Data for this endpoint is not final but it is not deemed to change significantly moving forward.

                          Brand Name : Modufolin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 07, 2022

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

                          Brand Name : Arfox

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 22, 2022

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Arfox (Arfolitixorin), is the first and only immediately active folate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer.

                          Brand Name : Arfox

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 03, 2021

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : As the first and only pure form of the folate ([6R]-MTHF) that increases 5FU-cytotoxicity, arfolitixorin is currently being evaluated in the global pivotal Phase III AGENT study used for treatment of patients with metastatic colorectal cancer (mCRC).

                          Brand Name : Arfox

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 23, 2021

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The patent application that will be granted includes a dose regimen involving two or more injections of arfolitixorin in combination with 5-fluorouracil (5-FU).

                          Brand Name : Arfox

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 22, 2021

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The iDSMB has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin. Isofol expects the top line results for the AGENT study to be available during H1 202...

                          Brand Name : Arfox

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 19, 2021

                          Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combinat...

                          Brand Name : Modufolin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 15, 2021

                          Lead Product(s) : Arfolitixorin,Fluorouracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Isofol’s drug candidate, arfolitixorin, is evaluated for treatment of patients with first-line metastatic colorectal cancer (mCRC). The AGENT study is currently being conducted in the U.S., Canada, Europe, Australia and Japan at more than 90 clinics.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 09, 2020

                          Lead Product(s) : Arfolitixorin,Oxaliplatin,Fluorouracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $103.0 million

                          November 02, 2020

                          Lead Product(s) : Arfolitixorin,Oxaliplatin,Fluorouracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : PALADIN LABS

                          Deal Size : $100.0 million

                          Deal Type : Licensing Agreement

                          blank